Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

UBS
Farmers Insurance
Federal Trade Commission
Merck
Cantor Fitzgerald
Fish and Richardson
US Department of Justice
Novartis
Express Scripts
McKinsey

Generated: August 21, 2017

DrugPatentWatch Database Preview

Luitpold Company Profile

« Back to Dashboard

What is the competitive landscape for LUITPOLD, and what generic alternatives to LUITPOLD drugs are available?

LUITPOLD has ninety-four approved drugs.

There are four US patents protecting LUITPOLD drugs.

There are fifty-six patent family members on LUITPOLD drugs in thirty countries.

Summary for Applicant: Luitpold

Patents:4
Tradenames:75
Ingredients:72
NDAs:94
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Luitpold
CIMETIDINE HYDROCHLORIDE
cimetidine hydrochloride
INJECTABLE;INJECTION074353-001Dec 20, 1994DISCNNoNo► Subscribe► Subscribe► Subscribe
Luitpold
CALCITRIOL
calcitriol
INJECTABLE;INJECTION075746-002Sep 26, 2003DISCNNoNo► Subscribe► Subscribe► Subscribe
Luitpold
DOPAMINE HYDROCHLORIDE
dopamine hydrochloride
INJECTABLE;INJECTION070820-001Feb 11, 1987APRXNoYes► Subscribe► Subscribe► Subscribe
Luitpold
ONDANSETRON HYDROCHLORIDE
ondansetron hydrochloride
INJECTABLE;INJECTION079039-001Nov 18, 2008APRXNoNo► Subscribe► Subscribe► Subscribe
Luitpold
TRIMETHOBENZAMIDE HYDROCHLORIDE PRESERVATIVE FREE
trimethobenzamide hydrochloride
INJECTABLE;INJECTION091329-001Mar 8, 2011APRXNoNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Luitpold

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Luitpold
DEXFERRUM
iron dextran
INJECTABLE;INJECTION040024-001Feb 23, 1996► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Luitpold

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,431,549Methods and compositions for administration of iron► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Luitpold Drugs

Country Document Number Estimated Expiration
South Korea20170028449► Subscribe
Norway335770► Subscribe
Denmark1554315► Subscribe
South Korea20050070014► Subscribe
Spain2364136► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Luitpold Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
02/028Ireland► SubscribePRODUCT NAME: VALGANCICLOVIR (2-(2-AMINO-1,6-DIHYDRO-6-OXO-PURIN-9-YL)- METHOXY-3-HYDROXY-1-PROPANYL-L-VALINATE) AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; NAT REGISTRATION NO/DATE: 50/150/1 20020913; FIRST REGISTRATION NO/DATE: NL 25992 20010920; PAEDIATRIC INVESTIGATION PLAN: P/0220/2013
2009Austria► SubscribePRODUCT NAME: KOMBINATION AUS ESTRADIOLVALERAT UND DIENOGEST; NAT. REGISTRATION NO/DATE: 1-28003 20090203; FIRST REGISTRATION: BE BE 327792 20081103
C/GB98/030United Kingdom► SubscribePRODUCT NAME: FOSPHENYTOIN SODIUM (3-HYDROXYMETHYL)-5,5-DIPHENYLHYDANTOIN DISODIUM PHOSPHATE ESTER); REGISTERED: UK 0019/0157 19980204
C/GB08/020United Kingdom► SubscribeSUPPLEMENTARY PROTECTION CERTIFICATE NO SPC/GB08/020 GRANTED TO ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. IN RESPECT OF THE PRODUCT RALTEGRAVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, ESPECIALLY THE POTASSIUM SALT, THE GRANT OF WHICH WAS ADVERTISED IN JOURNAL NO 6346 DATED 05 JANUARY 2011 HAS HAD ITS MAXIMUM PERIOD OF DURATION CORRECTED, SUBJECT TO THE PAYMENT OF THE PRESCRIBED FEES IT WILL EXPIRE ON 01 JANUARY 2023.
C0012Belgium► SubscribePRODUCT NAME: OLANZAPINE; REGISTRATION NO/DATE: EU/1/96/022/001 19960927
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Colorcon
Citi
Dow
Healthtrust
Fuji
US Department of Justice
Daiichi Sankyo
Cipla
Cantor Fitzgerald
UBS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot